Search clinical trials for: Low dose of Recombinant COVID-19 Trivalent (XBB BA.5 Delta) Protein Vaccine (Sf9 Cell)

Total 30 results

WestVac Biopharma Co., Ltd.

Not yet recruiting

A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination

COVID-19
WestVac Biopharma Co., Ltd.

Not yet recruiting

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination

COVID-19
WestVac Biopharma Co., Ltd.
WestVac Biopharma (Guangzhou) Co., Ltd.

Recruiting

A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

COVID-19

China
WestVac Biopharma Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

COVID-19

China
Jiangsu Province Centers for Disease Control and...
West China Hospital

Completed

A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)

COVID-19

China
WestVac Biopharma Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)

COVID-19

China
AIM Vaccine Co., Ltd.
First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...

Active, not recruiting

A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China

SARS-CoV-2

China
WestVac Biopharma Co., Ltd.
West China Hospital

Completed

A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

China
Sinovac Biotech (Colombia) S.A.S.
Sinovac Life Sciences Co., Ltd.

Not yet recruiting

Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated

COVID-19

Colombia
WestVac Biopharma Co., Ltd.

Completed

Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

Philippines
WestVac Biopharma Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

Mexico
Zhongnan Hospital
Institute of Biotechnology, Academy of Military Medical Sciences, PLA of...

Recruiting

A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes

COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
First Affiliated Hospital Bengbu Medical College

Completed

Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)

COVID-19

China
CanSino Biologics Inc.

Withdrawn

A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine

COVID-19
Pfizer

Recruiting

Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California

COVID-19

United States
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Lanzhou Institute of Biological... and other collaborators

Recruiting

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Coronavirus Infections | COVID-19 Pneumonia

United Arab Emirates
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Not yet recruiting

Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

Coronavirus
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

Coronavirus

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Hunan Provincial Center for Disease Control and Prevention

Not yet recruiting

Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial

COVID-19
Jiangsu Province Centers for Disease Control and...

Completed

Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine

COVID-19

China
Clover Biopharmaceuticals AUS Pty Ltd

Withdrawn

Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults

COVID-19

Philippines
Jiangsu Province Centers for Disease Control and...
Academy of Military Medical Sciences，Academy of Military Sciences，PLA ZHONGYIANKE...

Recruiting

Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)

COVID-19

China
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...

United States
M.D. Anderson Cancer Center

Completed

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | AIDS-Related Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI); EsPhALL Network/ BFM Study Group

Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel
National Cancer Institute (NCI)

Recruiting

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States, Puerto Rico, Israel
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

HIV Infections

United States, Puerto Rico, Thailand, Botswana, Argentina, Brazil, Tanzania, South Africa
National Cancer Institute (NCI)

Completed

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States, Canada, Australia, New Zealand, Puerto Rico

Search clinical trials for: Low dose of Recombinant COVID-19 Trivalent (XBB BA.5 Delta) Protein Vaccine (Sf9 Cell)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations